The predictive value of 18F-FDG-PET in the early detection of residual disease after larynx organ preserving chemoradiation;Diagnostik mittels 18F-FDG-PET nach larynxorganerhalt durch primäre radiochemotherapie

HNO

Volumn 52, Issue 1, 2004, Pages 38-44

  Dietz, A ^a   Rudat, V ^b   Harms, W ^c   Jungehulsing M ^d   Dollner, R ^a   Henze, M ^c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Klinikum Ernst V Bergmann   (Germany)

Author keywords

Chemoradiation; Hypopharyngeal carcinoma; Laryngeal carcinoma; Larynx organ preservation; PET

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; GLUCOSE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; GLUCOSE METABOLISM; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MINIMAL RESIDUAL DISEASE; ORGAN PRESERVATION; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED RADIOTHERAPY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HYPOPHARYNX TUMOR; IMAGE PROCESSING; LARYNGECTOMY; LARYNX TUMOR; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; SALVAGE THERAPY; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

AGED; BLOOD GLUCOSE; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; IMAGE PROCESSING, COMPUTER-ASSISTED; LARYNGEAL NEOPLASMS; LARYNGECTOMY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIATION DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0842327400     PISSN: 00176192     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00106-003-0890-2     Document Type: Article

References (17)

1. Berlangieri SU, Brizel DM, Scher RL et al. (1994) Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck 16/4: 340-346
2. Brun E, Kjellen E, Tennvall J et al. (2002) FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 24/2: 127-135
3. Dietz A, Rudat V, Nollert J et al. (2001) Organerhalt beim fortgeschrittenen Larynx-, bzw. Hypopharynxkarzinom durch primäre Radiochemotherapie - Ergebnisse einer multizentrischen Phase-II-Studie. HNO 50: 146-154
4. Dietz A, Rudat V, Nollert J, Helbig M, Vanselow B (1998) Das chronische Larynxödem als Spätreaktion nach Radiochemotherapie. HNO 46: 731-738
5. Keyes JW Jr, Watson NE Jr (2001) Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 23/11: 942-946
6. Greven KM, Williams DW 3rd, Keyes JW Jr et al. (1994) Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation. Cancer 74/4: 1355-1359
7. Henze M, Mohammed A, Mier W et al. (2002) Pretreatment evaluation of carcinomas of the hypopharynx and larynx with (18)F-fluorodeoxyglucose, (123)I-alpha-methyl-L-tyrosine and (99m)Tc-hexakis-2-methoxyl-sobutylisonitrile. Eur J Nucl Med 29/3: 324-330
8. Keyes JW, Watson NE, Williams DW 3rd, Greven KM, McGuirt WF (1997) FDG PET in head and neck cancer. AJR Am J Roentgenol 169/6: 1663-1669
9. Lefebvre JL, Chevalier D, Luboinski B et al. (1996) Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88/13: 890-899
10. Lowe VJ, Dunphy FR, Varvares M et al. (1997) Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18] fiuorodeoxyglucose positron emission tomography. Head Neck 19/8: 666-674
11. McGuirt WF, Greven K, Williams D 3rd et al. (1998) PET scanning in head and neck oncology: a review. Head Neck 20/3: 208-215
12. Mendenhall WM, Mancuso AA, Parsons JT, Stringer SP, Cassisi NJ (1998) Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck 20/8: 739-744
13. Narayan K, Crane CH, Kleid S, Hughes PG, Peters LJ (1999) Planned neck dissection as an adjunct to the management of patients with advanced neck disease treated with definitive radiotherapy: for some or for all? Head Neck 21/7: 606-613
14. Schipper JH, Schrader M, Arweiler D, Muller S, Sciuk J (1996) Die Positronenemissionstomographie zur Primärtumorsuche bei Halslymphknoten-metastasen mit unbekanntem Primärtumor. HNO 44/5: 254-257
15. Stoeckli SJ, Steinert H, Pfaltz M, Schmid S (2002) Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma? Head Neck 24: 345-349
16. Teknos TN, Rosenthal EL, Lee D, Taylor R, Marn CS (2001) Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 23/12: 1056-1060
17. The Department of Veterans Affairs Laryngeal Cancer Study Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324/24: 1685-1690